Bristol-Myers Squibb Company (BMY) — Fair Value Analysis

Base-case fair value (P50): $64.42 · Current price: $63.83 · Verdict: Fairly Valued

The Verdict on BMY

Bristol Myers Squibb (BMY) is currently Fairly Valued based on our Monte Carlo simulations. At a $63.83, the Healthcare sector giant trades remarkably close to its median fair value (P50) of $64.42, indicating very limited potential +0.9%. This assessment suggests that current market pricing accurately reflects BMY's intrinsic value under a wide range of future scenarios, despite the company's "weak" quality tier relative to its sector peers. Investors should note this narrow spread between current price and simulated fair value.

How BMY stacks up against Healthcare

Despite operating within the robust Healthcare sector, BMY's "weak" quality tier signals underlying operational or financial challenges when benchmarked against industry peers. Even with this quality tier, our simulations indicate that $63.83 aligns closely with the $64.42 fair value. This suggests that the market may already be pricing in the implications of its "weak" quality. For a stock with a "weak" quality designation, a "Fairly Valued" verdict with only +0.9% potential implies a lack of significant mispricing or attractive entry points for value-seeking investors based purely on our Monte Carlo findings.

What this means for investors

For investors considering BMY, the current valuation indicates minimal mispricing. With $63.83 hovering near $64.42 and only +0.9% apparent upside, the Monte Carlo simulations do not flag BMY as a compelling value opportunity, especially given its "weak" quality tier. While this doesn't imply an overvaluation, it suggests limited room for appreciation from current levels, at least according to the median outcome of thousands of simulated futures. To understand the full range of possibilities, including potential downside scenarios and more optimistic bull cases, sign up for a free FairCurve account. You can then track BMY's fair value as new fundamentals are released and explore the complete bear/bull distribution.